ArticleDrug design, development and therapy2025
Allicin Aplealleviates Gouty Arthritis by Regulating the Gut-Joint Axis, Reducing XOD Activity, Inhibiting Oxidative Stress, and Suppressing NLRP3 Inflammasome Activation.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Therapeutic Potential of Allicin in Multi-System Inflammatory Diseases.Current issues in molecular biology · 2026Review
- Mechanisms of Gut Microbiota-Derived Metabolites in Treating Hyperuricemia: Natural Products as Interventions.Molecules (Basel, Switzerland) · 2026Review
- Therapeutic potential of allicin against viral infections: Mechanisms and safety profile (Review).Experimental and therapeutic medicine · 2026Review
- Intestinal Multi-Target Mechanisms of Natural Active Substances in Hyperuricemia Alleviation: Recent Progress.Nutrients · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gouty arthritis (GA) is a common joint inflammation closely related to hyperuricemia and urate crystal deposition, and its incidence is on the rise worldwide. Allicin, the primary biologically active component found in freshly crushed garlic extracts, has been reported to possess many beneficial biological functions. Methods: An animal model was used to evaluate the efficacy of allicin on GA rats, and 16S rRNA sequencing and metabolomics were used to explore changes in the gut microbiota and metabolites. Fecal microbiota transplantation (FMT) and fibroblast-like synoviocytes (FLS) used to explore the mechanism of allicin treating GA. Results: The results showed that allicin effectively improved the general state of GA rats, inhibited XOD activity, and significantly reduced ROS production and activation of the NLRP3 inflammasome, thereby exerting therapeutic efficacy to protect the kidneys and joints. Examination of the gut microbiota showed that the composition of the gut microbiota of GA rats improved after allicin treatment (increase in Conclusion: This study highlights allicin as a promising therapeutic candidate for GA, emphasizing its potential to inhibit oxidative stress and inflammatory responses by regulating the gut-joint axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.